ZFIN Fish: b1212Tg

ZFIN ID: ZDB-FISH-150901-25885

Fish name:	b1212Tg
Genotype:	b1212Tg
Targeting Reagent:	none

HUMAN DISEASE MODELED by b1212Tg

Human Disease	Conditions	Citations
glucocorticoid-induced osteoporosis	chemical treatment by environment: dexamethasone	Zhong et al., 2021

GENE EXPRESSION
Gene expression in b1212Tg

RNA expression No data available

Protein expression

Antibody	Antigen Genes	Structure	Conditions	Figures
Ab1-sp7		cranial vault osteoblast frontal bone osteoblast parietal bone osteoblast	standard conditions	Fig. 5 , Fig. 5-S1 , Fig. 5-S2 from Teng et al., 2018
Ab1-thbs4b		ligament operculohyoid ligament extracellular matrix tendon	standard conditions	Fig. 2 , Fig. S2 from Nichols et al., 2016
Ab12-GFP	EGFP	inter-frontal joint	standard conditions	Fig. 7 from Topczewska et al., 2016

Reporter gene expression

Expressed Gene	Structure	Conditions	Figures
EGFP	branchiostegal ray osteoblast ceratobranchial 5 bone osteoblast cleithrum osteoblast cranium osteoblast inter-frontal joint interopercle mandibular arch skeleton osteoblast opercle postero-ventral margin osteoblast unspecified	control	15 figures from 7 publications
	cranium osteoblast unspecified	chemical treatment by environment: dexamethasone	Fig. 6 from Zhong et al., 2021 Fig. 2, Fig. 4, Fig. 7 from Luo et al., 2016 Fig. 8 from Huycke et al., 2012

PHENOTYPE
Phenotype in b1212Tg

Phenotype	Conditions	Figures
cranium bone mineralization disrupted, abnormal	chemical treatment by environment: dexamethasone	Fig. 6 from Zhong et al., 2021
cranium bone mineralization process quality, ameliorated	chemical treatment by environment: quercetin, chemical treatment by environment: dexamethasone	Fig. 6 from Zhong et al., 2021
cranium osteoblast EGFP expression amount, ameliorated	chemical treatment by environment: dexamethasone, chemical treatment by environment: calcitriol	Fig. 7 from Luo et al., 2016
cranium osteoblast EGFP expression amount, ameliorated	chemical treatment by environment: salvianolic acid B, chemical treatment by environment: dexamethasone	Fig. 7 from Luo et al., 2016
cranium osteoblast EGFP expression decreased amount, abnormal	chemical treatment by environment: dexamethasone	Fig. 2, Fig. 7 from Luo et al., 2016
cranium osteoblast EGFP expression decreased distribution, abnormal	chemical treatment by environment: dexamethasone	Fig. 2, Fig. 7 from Luo et al., 2016
cranium osteoblast EGFP expression decreased distribution, abnormal	chemical treatment by environment: dexamethasone	Fig. 6 from Zhong et al., 2021
cranium osteoblast EGFP expression increased amount, abnormal	chemical treatment by environment: salvianolic acid B	Fig. 4 from Luo et al., 2016
cranium osteoblast EGFP expression increased distribution, abnormal	chemical treatment by environment: salvianolic acid B	Fig. 4 from Luo et al., 2016
cranium osteoblast EGFP expression position, ameliorated	chemical treatment by environment: quercetin, chemical treatment by environment: dexamethasone	Fig. 6 from Zhong et al., 2021
cranium osteoblast differentiation decreased occurrence, abnormal	chemical treatment by environment: dexamethasone	Fig. 2, Fig. 7 from Luo et al., 2016
cranium osteoblast differentiation increased occurrence, abnormal	chemical treatment by environment: salvianolic acid B	Fig. 4 from Luo et al., 2016
cranium osteoblast differentiation occurrence, ameliorated	chemical treatment by environment: salvianolic acid B, chemical treatment by environment: dexamethasone	Fig. 7 from Luo et al., 2016
cranium osteoblast differentiation occurrence, ameliorated	chemical treatment by environment: dexamethasone, chemical treatment by environment: calcitriol	Fig. 7 from Luo et al., 2016
opercle postero-ventral margin decreased length, abnormal	chemical treatment: Cyclopamine	Fig. 8 from Huycke et al., 2012

CITATIONS (17)